Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 10/20 | 0.48 |
| ▸ | TMPRSS6 | Q8IU80 | 4/20 | 0.48 |
| ▸ | F10 | P00742 | 5/20 | 0.44 |
| ▸ | PLG | P00747 | 4/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.44 |
| ▸ | PROC | P04070 | 1/20 | 0.44 |
| ▸ | MASP2 | O00187 | 2/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | TMPRSS11D | O60235 | 5/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.40 |
| ▸ | RELA | Q04206 | 2/20 | 0.40 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17381407 | 0.90 | F2 (0.44) | F2TMPRSS6F10PLGKLKB1 | |
| SCHEMBL2562907 | 0.89 | F2 (0.48) | F2F10PLGKLKB1PROC | |
| SCHEMBL2562905 | 0.89 | F2 (0.48) | F2F10PLGKLKB1PROC | |
| SCHEMBL12127052 | 0.89 | F2 (0.44) | F2F10PLGKLKB1PROC | |
| SCHEMBL17366106 | 0.87 | F2 (0.62) | F2TMPRSS6F10PLGKLKB1 | |
| SCHEMBL17381506 | 0.87 | F2 (0.62) | F2TMPRSS6F10PLGKLKB1 | |
| SCHEMBL20117449 | 0.84 | MASP2 (0.43) | F2TMPRSS6KLKB1MASP2MMP12 | |
| SCHEMBL18875515 | 0.81 | F2 (0.45) | F2TMPRSS6F10PLGKLKB1 | |
| SCHEMBL18875317 | 0.80 | F2 (0.49) | F2F10PLGKLKB1PROC | |
| SCHEMBL17366097 | 0.80 | F2 (0.49) | F2F10PLGKLKB1PROC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145054-A1 | PROCESS FOR THE PRODUCTION OF A DIPEPTIDE DERIVATIVE | DSM IP ASSETS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| US-20170145054-A1 | PROCESS FOR THE PRODUCTION OF A DIPEPTIDE DERIVATIVE | DSM IP ASSETS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| WO-2015197309-A1 | PROCESS FOR THE PRODUCTION OF A DIPEPTIDE DERIVATIVE | DSM IP ASSETS B.V. (NL) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145054-A1 | PROCESS FOR THE PRODUCTION OF A DIPEPTIDE DERIVATIVE | VIP, PEPD, DNPEP | F2 410/4885TMPRSS6 170/4885F10 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.